Prothena Announces Novo Nordisk Obtains Fast Track Designation from the U.S. FDA for Coramitug in ATTR Amyloidosis with Cardiomyopathy
Prothena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights
Prothena's Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 , an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of Alzheimer's Disease
SAGA Metals Highlights Radar Project's VTM Enriched Magnetic Concentrate up to 0.9% V2O5 Relative to Panzhihua, China Benchmark of 0.3% V2O5
Brixton Metals Commences Drilling for Maiden Tailings Mineral Resource Estimate at the Langis Silver Project
